CDC20 facilitates the proliferation of esophageal carcinoma cell by stabilizing NLRP3 expression

doi:10.19401/j.cnki.1007-3639.2024.05.004

Abstract

Abstract:

Background and purpose: Esophageal carcinoma (ESCA) is one of the malignant tumors with high mortality rate, and the underlying mechanism of its development is largely unknown. CDC20 plays an important role in tumorigenesis, and its dysregulated expression is closely related to tumor occurrence and development. The expression of CDC20 is increased in a variety of tumors, and knocking down CDC20 can inhibit tumor cell proliferation. NLRP3 is the main component of the inflammasome, and inflammasome is also closely related to tumor occurrence and development. Here, our study aimed to investigate whether CDC20 promotes the proliferation of ESCA cells through NLRP3 and its regulatory mechanism. Methods: The expression levels of CDC20 and NLRP3 genes in ESCA patients were analyzed using The Cancer Genome Atlas (TCGA) detabase and GTEx public database. We collected clinical and pathological data and tissues from 80 ESCA patients at the First Affiliated Hospital of Xinxiang Medical College, and detected the protein expression of NLRP3 in ESCA patients through immunohistochemistry staining. This study was approved by the Ethics Committee of the First Affiliated Hospital of Xinxiang Medical College (Number: EC-021-137). We studied the effects of knocking down CDC20 and NLRP3 gene on the proliferation ability of esophageal squamous cell carcinoma cells EC9706 and KYSE150 using short hairpin RNA (shRNA) technology. Co-immunoprecipitation (Co-IP), proteasome inhibitors and ubiquitination experiments were used to detect whether CDC20 interacts with NLRP3, and to elucidate whether CDC20 regulates NLRP3 expression through the ubiquitination pathway. This study was approved by the Ethics Committee of the First Affiliated Hospital of Xinxiang Medical College (Number: EC-021-137). Results: The TCGA database analysis showed that the expression levels of CDC20 and NLRP3 mRNA were significantly higher in the cancer tissues of ESCA patients than in the adjacent tissues. The immunohistochemistry results further showed that compared with adjacent tissues, the protein expression levels of CDC20 and NLRP3 were increased in ESCA tissues. Knocking down CDC20 and NLRP3 genes inhibited the proliferation of ESCA cells. Co-IP, proteasome inhibitors and ubiquitination experiments confirmed that CDC20 interacted with NLRP3 through its leucine-rich repeat (LRR), and CDC20 stabilized its expression by promoting NLRP3 ubiquitination. Conclusion: CDC20 and NLRP3 are upregulated in ESCA tissues, and CDC20 stabilizes their expression through ubiquitination of NLRP3, promoting ESCA cell proliferation. This suggests that CDC20 and NLRP3 may be potential diagnostic targets for ESCA.

Key words: Esophageal carcinoma, CDC20, NLRP3, Ubiquitination, Proliferation

CLC Number:

R735.1

GUAN Ruirui, HAO Qian, ZHANG Yaqi, SUN Qinggang, CHEN Yitian, LI Xiumin, ZHOU Xiang, HAN Tao. CDC20 facilitates the proliferation of esophageal carcinoma cell by stabilizing NLRP3 expression[J]. China Oncology, 2024, 34(5): 473-484.

Figures/Tables 6

Fig. 1

Fig. 2

Tab. 1

Fig. 3

Fig. 4

Fig. 5

References 38

[1]	FATEHI HASSANABAD A, CHEHADE R, BREADNER D, et al. Esophageal carcinoma: towards targeted therapies[J]. Cell Oncol, 2020, 43(2): 195-209.
[2]	ZHANG Y W. Epidemiology of esophageal cancer[J]. World J Gastroenterol, 2013, 19(34): 5598-5606.
[3]	SAEI GHARE NAZ M, KARIMAN N, EBADI A, et al. Educational interventions for cervical cancer screening behavior of women: a systematic review[J]. Asian Pac J Cancer Prev, 2018, 19(4): 875-884.
[4]	CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[5]	HAN T, JIANG S L, ZHENG H, et al. Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis[J]. Nat Commun, 2019, 10(1): 3716.
[6]	WAN L X, CHEN M, CAO J X, et al. The APC/C E3 ligase complex activator FZR1 restricts BRAF oncogenic function[J]. Cancer Discov, 2017, 7(4): 424-441.
[7]	HUANG H C, SHI J, ORTH J D, et al. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly[J]. Cancer Cell, 2009, 16(4): 347-358.
[8]	MANCHADO E, GUILLAMOT M, DE CÁRCER G, et al. Targeting mitotic exit leads to tumor regression in vivo: modulation by Cdk1, Mastl, and the PP2A/B55α, δ phosphatase[J]. Cancer Cell, 2010, 18(6): 641-654.
[9]	ZHANG Q, HUANG H, LIU A, et al. Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of β-catenin in cancer stem-like cells[J]. EBioMedicine, 2019, 42: 397-407. doi: S2352-3964(19)30172-0 pmid: 30904606
[10]	KARRA H, REPO H, AHONEN I, et al. CDC20 and securin overexpression predict short-term breast cancer survival[J]. Br J Cancer, 2014, 110(12): 2905-2913.
[11]	JI P, SMITH S M, WANG Y, et al. Inhibition of gliomagenesis and attenuation of mitotic transition by MIIP[J]. Oncogene, 2010, 29(24): 3501-3508. doi: 10.1038/onc.2010.114 pmid: 20418911
[12]	KIM J M, SOHN H Y, YOON S Y, et al. Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells[J]. Clin Cancer Res, 2005, 11(2 Pt 1): 473-482.
[13]	XIE Q, WU Q L, MACK S C, et al. CDC20 maintains tumor initiating cells[J]. Oncotarget, 2015, 6(15): 13241-13254. pmid: 25938542
[14]	JIANG J H, JEDINAK A, SLIVA D. Ganodermanontriol (GDNT) exerts its effect on growth and invasiveness of breast cancer cells through the down-regulation of CDC20 and uPA[J]. Biochem Biophys Res Commun, 2011, 415(2): 325-329.
[15]	HE S D, LIU D P, CHEN Z H. REC8 inhibits proliferation, migration and invasion of breast cancer cells by targeting CDC20[J]. Mol Med Rep, 2022, 26(1): 235.
[16]	PAUL D, GHORAI S, DINESH U S, et al. CDC20 directs proteasome-mediated degradation of the tumor suppressor SMAR1 in higher grades of cancer through the anaphase promoting complex[J]. Cell Death Dis, 2017, 8(6): e2882.
[17]	YANG G, WANG G, XIONG Y F, et al. CDC20 promotes the progression of hepatocellular carcinoma by regulating epithelial-mesenchymal transition[J]. Mol Med Rep, 2021, 24(1): 483.
[18]	MARUCCI G, MORANDI L, MAGRINI E, et al. Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20[J]. Virchows Arch, 2008, 453(6): 599-609. doi: 10.1007/s00428-008-0685-7 pmid: 18953566
[19]	OUELLET V, GUYOT M C, PAGE C L, et al. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer[J]. Int J Cancer, 2006, 119(3): 599-607. pmid: 16572426
[20]	SAGOO P, GARCIA Z, BREART B, et al. In vivo imaging of inflammasome activation reveals a subcapsular macrophage burst response that mobilizes innate and adaptive immunity[J]. Nat Med, 2016, 22(1): 64-71.
[21]	HE Y, HARA H, NÚÑEZ G. Mechanism and regulation of NLRP3 inflammasome activation[J]. Trends Biochem Sci, 2016, 41(12): 1012-1021. doi: S0968-0004(16)30148-7 pmid: 27669650
[22]	THI H T H, HONG S. Inflammasome as a therapeutic target for cancer prevention and treatment[J]. J Cancer Prev, 2017, 22(2): 62-73. doi: 10.15430/JCP.2017.22.2.62 pmid: 28698859
[23]	GRIVENNIKOV S I, GRETEN F R, KARIN M. Immunity, inflammation, and cancer[J]. Cell, 2010, 140(6): 883-899. doi: 10.1016/j.cell.2010.01.025 pmid: 20303878
[24]	PEI H P, TAN F B, LIU L, et al. IL-1β/NF-kb signaling promotes colorectal cancer cell growth through miR-181a/PTEN axis[J]. Arch Biochem Biophys, 2016, 604: 20-26. doi: 10.1016/j.abb.2016.06.001 pmid: 27264420
[25]	BAE J Y, LEE S W, SHIN Y H, et al. P2X7 receptor and NLRP3 inflammasome activation in head and neck cancer[J]. Oncotarget, 2017, 8(30): 48972-48982. doi: 10.18632/oncotarget.16903 pmid: 28430665
[26]	SIEGEL R, MA J, ZOU Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29.
[27]	WANG W B, XIAO F, WAN P, et al. EV71 3D protein binds with NLRP3 and enhances the assembly of inflammasome complex[J]. PLoS Pathog, 2017, 13(1): e1006123.
[28]	GUARDA G, ZENGER M, YAZDI A S, et al. Differential expression of NLRP3 among hematopoietic cells[J]. J Immunol, 2011, 186(4): 2529-2534. doi: 10.4049/jimmunol.1002720 pmid: 21257968
[29]	GWYER FINDLAY E, HUSSELL T. Macrophage-mediated inflammation and disease: a focus on the lung[J]. Mediators Inflamm, 2012, 2012: 140937.
[30]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[31]	YU S, YIN J J, MIAO J X, et al. Activation of NLRP3 inflammasome promotes the proliferation and migration of esophageal squamous cell carcinoma[J]. Oncol Rep, 2020, 43(4): 1113-1124. doi: 10.3892/or.2020.7493 pmid: 32323780
[32]	ALIDINA A, SIDDIQUI T, BURNEY I, et al. Esophageal cancer: a review[J]. J Pak Med Assoc, 2004, 54(3): 136-141.
[33]	MIMURA K, YAMADA L, UJIIE D, et al. Immunotherapy for esophageal squamous cell carcinoma: a review[J]. Fukushima J Med Sci, 2018, 64(2): 46-53. doi: 10.5387/fms.2018-09 pmid: 30058598
[34]	SAYAN M, MOSSMAN B T. The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases[J]. Part Fibre Toxicol, 2016, 13(1): 51.
[35]	CAO Z W, FANG Y L, LU Y H, et al. Exposure to nickel oxide nanoparticles induces pulmonary inflammation through NLRP3 inflammasome activation in rats[J]. Int J Nanomedicine, 2016, 11: 3331-3346.
[36]	吕本洁, 周孝峰, 王伟隆, 等. 食管鳞癌组织Snail与PDL-1和CD8⁺T表达及预后分析[J]. 中华肿瘤防治杂志, 2023, 30(2): 78-83.
[37]	LYU B J, ZHOU X F, WANG W L, et al. Correlation and prognostic analysis of Snail with PD-L1 and CD8⁺T in esophageal squamous cell carcinoma[J]. Chin J Cancer Prev Treat, 2023, 30(2): 78-83.
[38]	GOMES-SANTOS I L, AMOOZGAR Z, KUMAR A S, et al. Exercise training improves tumor control by increasing CD8⁺T-cell infiltration via CXCR3 signaling and sensitizes breast cancer to immune checkpoint blockade[J]. Cancer Immunol Res, 2021, 9(7): 765-778.

Pathologic feature	Total n	CDC20 expression n		χ² value	P value	NLRP3 expression n		χ² value	P value
Pathologic feature	Total n	High	Low	χ² value	P value	High	Low	χ² value	P value
Organizational classification				5.788	0.016			4.290	0.038
G1	54	24	30			36	18
G2-G3	26	19	7			11	15
Depth of infiltration				8.459	0.004			4.921	0.027
T1-T2	15	3	12			5	10
T3-T4	65	40	25			42	23
Lymph node metastasis				5.729	0.020			5.071	0.024
No	57	26	31			29	28
Yes	23	17	6			18	5
TNM staging
Ⅰ	27	9	18	3.884	0.049	13	14	3.884	0.049
Ⅱ	21	13	8			16	5
Ⅲ	25	19	6	5.153	0.020	17	8	6.412	0.011
Ⅳ	7	2	5			1	6